Is Korea Prepared for an Alzheimer’s Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests
Open Access
- 31 March 2021
- journal article
- research article
- Published by The Korean Geriatrics Society in Annals of Geriatric Medicine and Research
- Vol. 25 (1), 33-38
- https://doi.org/10.4235/agmr.20.0082
Abstract
Background: With the rapid demographic change in Korea, Alzheimer's disease has become a primary concern. Recent developments in disease-modifying therapies provide hope that therapy may become available soon. The high disease prevalence and complex evaluation process will create challenges for the healthcare system already burdened by the current pandemic. This study examined the preparedness of the South Korean healthcare system to identify and treat patients when such a therapy becomes available. Methods: We used a Markov model to simulate a stylized patient's journey. Based on national data and expert input, we presented projections of the diagnosis and treatment wait times and respective queues of patients under treatment and no-treatment scenarios and further simulated the possible option of adopting a blood-based bio-marker test. Results: Under the current system, we estimated a peak waiting time of 14 months when a treatment became available, largely because of the limited number of dementia specialists. Adopting a blood-based biomarker test dramatically reduced the initial wait times by more than half. A disease-modifying therapy was estimated to avert 575,000 incident cases in the first 10 years after the treatment entered the market, and a blood-based test further avoided 86,000 additional cases. Conclusion: South Korea's healthcare infrastructure requires more preparation for the introduction of a disease-modifying therapy, with the primary capacity limitation being the low number of dementia specialists. The utilization of a blood-based test for Alzheimer's disease biomarkers may be an effective solution.Keywords
Funding Information
- University of California
This publication has 22 references indexed in Scilit:
- Korean national dementia plans: from 1st to 3rdJournal of the Korean Medical Association, 2018
- Practice guideline update summary: Mild cognitive impairmentNeurology, 2018
- Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s diseaseAlzheimer's Research & Therapy, 2017
- Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in JapanClinicoEconomics and Outcomes Research, 2017
- Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of AgingJournal of Alzheimer's Disease, 2015
- Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.Current Alzheimer Research, 2012
- Present and Future of Korean GeriatricsJournal of the Korean Geriatrics Society, 2011
- The CERAD Neuropsychologic Battery Total Score and the Progression of Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2010
- Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studiesActa Psychiatrica Scandinavica, 2009
- Modeling the prevalence and incidence of Alzheimer’s disease and mild cognitive impairmentJournal of Psychiatric Research, 2002